Sensyne Partners With Excalibur To Improve Usability Of COVID-19 Tests
Sensyne has licensed its MagnifEye artificial intelligence technology to Excalibur Healthcare to improve the detection of COVID-19 infection at low viral loads.
You may also be interested in...
VALENCIA IA4COVID19’s AI model won the XPRIZE Pandemic Response Challenge grand prize. Researchers are pinning their hopes on AI to help predict the next pandemic, but also for early diagnosis of COVID-19.
Sensyne obtained UK regulatory approval for its SYNE-COV machine learning algorithm to assess the long-term risks of COVID-19.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.